SCHEMBL25833173

SCHEMBL25833173

CCCCC(C)C(=O)N1CCC2(CC1)CN(CCCC(C)CC)C2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 5/20 0.34
CYP2D6 P10635 8/20 0.34
TSHR P16473 4/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 4/20 0.32
CYP2C9 P11712 3/20 0.32
HIF1A Q16665 2/20 0.32
CYP2C19 P33261 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
CYP3A4 P08684 4/20 0.31
HSD17B10 Q99714 1/20 0.31
CCKBR P32239 1/20 0.31
ALDH1A1 P00352 1/20 0.31
EPHX2 P34913 1/20 0.30
S1PR4 O95977 1/20 0.30
S1PR1 P21453 1/20 0.30
S1PR3 Q99500 1/20 0.30
S1PR5 Q9H228 1/20 0.30
DRD2 P14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23696753 0.92 ACE2 (0.40) USP2CYP2D6TSHRCYP1A2CYP2C9
SCHEMBL25702522 0.91 CYP2D6 (0.34) USP2CYP2D6TSHRLMNACYP1A2
SCHEMBL25829588 0.90 ACE2 (0.41) USP2CYP2D6TSHRCYP1A2CYP2C9
SCHEMBL26405009 0.87 ACE2 (0.40) USP2CYP2D6TSHRLMNACYP1A2
SCHEMBL23696257 0.85 TSHR (0.44) USP2CYP2D6TSHRLMNACYP1A2
SCHEMBL23945863 0.84 ACE2 (0.39) USP2CYP2D6CYP3A4CCKBRALDH1A1
SCHEMBL25833674 0.84 CYP2D6 (0.36) USP2CYP2D6CYP3A4CCKBRALDH1A1
SCHEMBL27269749 0.82 CYP2D6 (0.39) USP2CYP2D6TSHRCYP1A2CYP2C9
SCHEMBL25123610 0.82 ACE2 (0.38) USP2CYP2D6TSHRLMNACYP1A2
SCHEMBL23807385 0.81 CYP2D6 (0.39) USP2CYP2D6TSHRCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 USP2 141/4885CYP2D6 3599/4885TSHR 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.